Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
141
resultados
Última actualización
21/11/2025 [07:24:00]
Resultados 125 a 141 de 141
Resumen de: KR20250141094A
본 발명의 일 예는 락티플란티바실러스 플란타룸(Lactiplantibacillus plantarum) KACC 11451 균주, 락티플란티바실러스 파라플란타룸(Lactiplantibacillus paraplantarum) KACC 12373 균주 또는 락티플란티바실러스 펜토수스(Lactiplantibacillus pentosus) KACC 12428 균주에서 선택되는 1종 이상의 균주 및 L-티로신을 포함하는 파킨슨병 예방, 개선 또는 치료용 조성물을 제공한다. 본 발명의 일 예에 따른 특정 유산균은 L-티로신의 레보도파로의 전환 활성이 매우 높다. 또한, 본 발명의 일 예에 따른 특정 유산균 및 L-티로신을 포함하는 조성물은 생체내에서 레보도파를 생산할 수 있도록 제형화될 수 있고, 파킨슨병의 예방, 개선 또는 치료를 위한 건강기능식품 또는 의약품으로 사용될 수 있다.
Resumen de: NZ766044A
The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates medicaments comprising gold (Au), barium titanate (BaTiO3) and/or zirconium dioxide (ZrO2) nanoparticles coated with a biocompatible coating providing a neutral or a negative surface charge, for preventing or treating Parkinson’s disease or Alzheimer’s disease by intra-cranial or intra-thecal administration and provided without exposure of the nanoparticles to an electric current, electric field or electric stimulus applied by deep brain stimulation (DBS), by transcranial electric stimulation (TES), or by transcranial magnetic stimulation (TMS).
Resumen de: KR20250140146A
본 발명의 일 예는 락티플란티바실러스 플란타룸(Lactiplantibacillus plantarum) KACC 11451 균주, 락티플란티바실러스 파라플란타룸(Lactiplantibacillus paraplantarum) KACC 12373 균주 또는 락티플란티바실러스 펜토수스(Lactiplantibacillus pentosus) KACC 12428 균주에서 선택되는 1종 이상의 균주 및 L-티로신을 포함하는 파킨슨병 예방, 개선 또는 치료용 조성물을 제공한다. 본 발명의 일 예에 따른 특정 유산균은 L-티로신의 레보도파로의 전환 활성이 매우 높다. 또한, 본 발명의 일 예에 따른 특정 유산균 및 L-티로신을 포함하는 조성물은 생체내에서 레보도파를 생산할 수 있도록 제형화될 수 있고, 파킨슨병의 예방, 개선 또는 치료를 위한 건강기능식품 또는 의약품으로 사용될 수 있다.
Resumen de: WO2025199206A1
Provided herein are medical uses of CD11a-enriched T regulatory cells for treating amyotrophic lateral sclerosis (ALS) or ameliorating a symptom of ALS. Such uses may include longitudinal analysis of biomarkers, such as inflammatory cytokines.
Resumen de: WO2025199234A1
This disclosure relates to, inter alia, certain compounds, compositions, and pharmaceutical compositions thereof, that modulate the activity of the transporter protein vesicular monoamine transporter- 2 (VMAT2) and are directed to methods useful in the treatment of transporter protein vesicular monoamine transporter-2 mediated disorders, such as, neurological or psychiatric disease or disorders, including but not limited to, hyperkinetic movement disorders (e.g., tardive dyskinesia, Tourette's syndrome, Huntington's disease, tics, ataxia, chorea (such as, chorea associated with Huntington's disease), dystonia, hemifacial spasm, myoclonus, restless leg syndrome, and tremors). The disclosure further relates to synthetic methods and intermediates useful in the preparation of compounds.
Resumen de: WO2025199451A2
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive or quality-of-life function.
Resumen de: AU2024232317A1
The present invention provides a pharmaceutical composition comprising metformin and glibenclamide for use in the treatment of Parkinson's disease. The invention also comprises a combined administration of metformin and glibenclamide. In a preferred embodiment, the administration is made through oral route.
Resumen de: US2025295603A1
Disclosed herein compositions and methods for the treatment of neurodegenerative disorders, such as Alzheimer's disease.
Resumen de: US2025296939A1
The present invention aims to provide a medicament capable of treating and/or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keap1 and Nrf2 and activating Nrf2. The present invention relates to a compound represented by the following formula (1):wherein each symbol is as described in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. In addition, the present invention also relates to a medicament containing the compound, for the prophylaxis and/or treatment of diseases involving oxidative stress selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, radiation skin disorder, radiation mucosal disorder, cardiac failure, pulmonary arterial hypertension, Parkinson's disease, Friedreich's ataxia, multiple sclerosis, age-related macular degeneration, retinitis pigmentosa and glaucoma.
Resumen de: WO2025199495A1
The present invention provides methods and compositions for reducing internalization and/or trafficking of tan in neuronal cells comprising contacting the cells with an effective amount of VLDL receptor antagonist. The invention further provides a method of treating or preventing Alzheimer's disease in a subject in need thereof, comprising administering to the subject an effective amount of a VLDL receptor antagonist.
Resumen de: WO2025199248A1
Applicants have discovered differential expression and activity of various miRNAs in neurodegenerative diseases. These miRNAs can serve as therapeutic targets for prevention and treatment of neurodegenerative diseases. Accordingly, embodiments of the invention include formulations and methods for treating neurodegenerative diseases such as dementia and Alzheimer's disease. The formulations and methods can include five microRNAs and two small molecule therapeutics. In aspects, the miRNAs are MIR-145-3p, let-7c-3p, MIR-383-5p, MIR-548aj-3p and MIR-548x-3p. In aspects, the small molecule therapeutics are GATC-49, fucosterol and fucoidan. In aspects, the compounds work synergistically with one another.
Resumen de: WO2025198916A1
The present disclosure provides anti-tau antibodies, including compositions and methods of using such antibodies for treating Alzheimer's disease.
Resumen de: WO2025194870A1
The present invention belongs to the technical field of biomedicine, and relates to a class of dexborneol or fenchyl alcohol ester derivatives of 2-hydroxynicotinic acid, and pharmaceutical uses thereof. The structural general formula of the derivatives is (1), R1 being selected from -H, -Cl, a hydrocarbon group having 1-8 carbon atoms, -CF3, -CF2H, -CN, -SCH3, -OH, -CHO, -CH2OH, -CH2NH2, -COOH, halogenated phenyl, or -NR4R5; R4, R5 are independently selected from -H or -CH3; R2 is selected from -H, an alkyl group having 1-6 carbon atoms, an acyl group having 2-7 carbon atoms, or a carbamoyl group; R 3 is selected from formula (a) or formula (b); X is selected from -CH= or -N=. The derivatives have good inflammation-inhibiting effects, and at high concentrations, they exhibit low cytotoxicity and are safer. The derivatives can be used for preparing a drug for treating inflammation and inflammation-related diseases such as stroke, neuropathic pain, depression and Alzheimer's disease.
Resumen de: US2025295627A1
A compound nitarsone, or salt thereof is provided for use in the treatment of a neurodegenerative disease, such as Alzheimer's disease (AD), dementia, Parkinson's disease (RD) or amyotrophic lateral sclerosis (ALS). A pharmaceutical composition is also provided that includes compound, or salt thereof for use in the treatment of a neurodegenerative disease.
Resumen de: EP4620471A2
Pridopidine or a pharmaceutically acceptable salt thereof for use in treating a subject afflicted with amyotrophic lateral sclerosis (ALS).
Nº publicación: EP4620959A1 24/09/2025
Solicitante:
SHANGHAI INST ORGANIC CHEMISTRY CAS [CN]
Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
Resumen de: EP4620959A1
The present invention discloses cyclic compounds as multi-target kinase inhibitors and preparation methods thereof. The multi-target kinase inhibitors of the present invention are as shown in general formula I, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>3a</sup>, L<sup>1</sup>, L<sup>2</sup>, L<sup>3</sup>, ring A, and ring B are as shown in the Specification and Claims. The present invention also discloses preparation methods of general formula I and its inhibitory activity against multiple kinases. The compounds of general formula I described in the present invention can be used for treating cancers and neurodegenerative diseases such as Parkinson's disease, etc.
BOPI
Sede Electrónica
